It appears you are asking about Humira and its relation to urinary tract infections (UTIs). Humira (adalimumab) is a medication used to treat various autoimmune diseases, such as rheumatoid arthritis, Crohn's disease, and psoriasis [1]. It works by blocking tumor necrosis factor-alpha (TNF-alpha), a protein that plays a role in inflammation [1].
Can Humira Cause UTIs?
Humira can increase the risk of infections, including urinary tract infections [2]. Because Humira suppresses the immune system, it can make it harder for the body to fight off bacteria that cause UTIs [2].
What Infections Are Associated with Humira?
Beyond UTIs, Humira can increase the risk of other serious infections. These include tuberculosis (TB), invasive fungal infections, bacterial infections, and viral infections [1]. Patients taking Humira should be aware of signs of infection, such as fever, fatigue, or unexplained aches and pains, and report them to their doctor immediately [2].
How Are Infections Managed in Patients on Humira?
Doctors screen patients for conditions like TB before starting Humira treatment [1]. During treatment, patients are monitored for signs of infection. If an infection develops, treatment with Humira may be paused or stopped, and the infection will be treated with appropriate medication [2].
What is Humira Used For?
Humira is prescribed for conditions characterized by chronic inflammation, including rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, ulcerative colitis, and plaque psoriasis [1]. It is not typically prescribed to treat UTIs themselves.
When Does Humira's Patent Expire?
The original patents for Humira have largely expired, allowing for the introduction of biosimilar versions [3]. Biosimilars are highly similar to the original biologic drug and are approved by regulatory agencies after demonstrating no clinically meaningful differences in safety, purity, and potency [4]. DrugPatentWatch.com tracks patent information for many medications, including those related to Humira [3].
What are the Humira Biosimilars?
Several biosimilar versions of adalimumab have been approved and are available in various markets. These biosimilars offer alternative treatment options for patients and healthcare providers [4].
What Are the Risks of Taking Humira?
The primary risks associated with Humira are related to its immunosuppressive effects, leading to an increased susceptibility to infections [2]. Other potential risks include allergic reactions, neurological events, and the development of certain cancers, though these are less common [1]. Patients should discuss all potential risks with their healthcare provider.